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High plasma levels of adrenomedullin in collagen diseases 
INTRODUCTION 
Rheumatic diseases result from abnormally 
regulated immune response, leading to 
inflammation of target organs 1. The disease process 
is usually assessed by the so called markers of 
disease activity, such as the number of swollen 
joints, erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP) and rheumatoid factor, in 
addition to radiographic evidence in JRA and by 
systemic lupus erythematosus-disease activity index 
(SLE-DAI) in SLE 2,3. However, the role of these 
nonspecific markers of inflammation, as markers of 
disease severity in established cases, is limited, so 
to monitor the disease course, newer markers need 
to document their superiority over the usual 
markers 4.  
Adrenomedullin (ADM) is a potent 
vasorelaxant / hypotensive peptide, initially isolated 
Original article 
Background: Adrenomedullin (ADM), a potent vasorelaxant/hypotensive 
peptide, was shown recently to be over-expressed in inflammatory rheumatic 
diseases.  
Objectives: The aim of this study was to investigate the value of ADM as a 
laboratory marker of disease activity in juvenile rheumatoid arthritis (JRA) 
and pediatric onset- systemic lupus erythematosus (SLE) and its relation to 
other markers of disease activity such as clinical scores, the ESR and tumor 
necrosis factor-α (TNF-α).  
Methods: The study included 24 patients with JRA, 17 with childhood onset- 
SLE, as well as, 19 with rheumatic arthritis and twenty clinically healthy 
age- and sex- matched subjects. Clinical evaluation for disease activity was 
performed using the clinical activity score index in JRA, and SLE-DAI in 
SLE. Subjects were investigated to verify the diagnosis and disease activity. 
Plasma ADM and serum of TNF-α levels were then assayed.  
Results: Serum TNF-α and plasma ADM levels were significantly higher in 
JRA and SLE patients than in rheumatic arthritis patients and healthy 
controls. Though serum TNF-α and plasma ADM levels were both higher in 
JRA (73.88+11.6 pg/ml and 156.5+22.4 pg/ml, respectively) compared to 
SLE (48.82+7.5 pg/ml and 85.12+15.7 pg/ml, respectively), the difference 
was of statistical significance only in ADM. Both serum TNF-α and plasma 
ADM levels were significantly higher in systemic onset-JRA (139.75+18.5 
and 260.25+28.6 pg/ml, respectively) compared to the pauciarticular-onset 
type (33.8+3.04 and 93.4+9.35 pg/ml, respectively), but comparable to the 
polyarticular onset cases (69.97+8.45 and 149.87+21.15 pg/ml, 
respectively). Positive correlations were noticed between plasma ADM and 
activity score index (r=0.72), ESR (r=0.59) and serum TNF-α (r=0.64) in 
JRA. The serum TNF- α was not influenced by the site of lupus activity 
unlike plasma ADM that was higher in subjects suffering from lupus arthritis 
or cardiovascular manifestations. The afore-mentioned markers correlated 
positively to the ESR in SLE but not to the SLE-DAI. With a cut-off value of 
TNF-α = 31 pg/ml and that for ADM = 80 pg/ml calculated from the results 
of the included rheumatic arthritis patients, ADM appeared to be a more 
sensitive marker of activity in JRA and SLE compared to TNF-α. 
Conclusion: Plasma ADM was over-expressed in JRA and SLE. It  
correlated with the clinical and biochemical activity markers in JRA 
suggesting that it can be used as an indicator of disease activity. In SLE, 
ADM levels correlated with ESR and TNF- α levels and it could be of value 
in identifying patients with arthritis and cardiac involvement. 
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and purified from the adrenal medulla and human 
pheochromocytoma 5. It is a 52 amino acid peptide 
that shows some homology with calcitonin gene-
related peptide (CGRP) and has been therefore 
added to the calcitonin/CGRP/amylin peptide 
family6. Studies showed that the gene is highly 
more expressed in endothelial cells, that this 
peptide has come to be regarded as a secretory 
peptide of the vascular endothelium, together with 
nitric oxide and endothelin7. In addition, ADM gene 
expression is seen in studies of other cultured cell 
lines e.g. leukocytes and macrophages 8.  
ADM has been shown to have a remarkable 
range of actions, from regulating cellular growth 
and differentiation, through modulating hormone 
secretion, to antimicrobial effect6. ADM production 
in vascular smooth muscle cells is highly 
augmented by TNF-α, IL-1 and lipopolysaccharides 
(LPS) suggesting that adrenomedullin participates 
in local regulation of vascular smooth muscle cell 
function, especially in cases of endotoxin shock, 
atherosclerosis and inflammation 9.  
Increased plasma adrenomedullin expression 
has been associated with a wide array of diseases 
including essential hypertension, acute myocardial 
infarction, chronic obstructive pulmonary diseases, 
chronic renal failure, glomerulonephritis, sepsis, 
Raynaud’s disease and Wegner granulomatosis6. 
Recent studies have shown that the production of 
ADM is elevated in inflammatory rheumatic 
diseases. Studies reported a correlation of ADM 
plasma levels with clinical and biochemical 
markers of activity in patients with rheumatoid 
arthritis10. 
We sought to investigate whether or not plasma 
level of ADM could be considered as a laboratory 
indicator of disease activity in juvenile rheumatoid 
arthritis (JRA) and childhood onset- systemic lupus 
erythematosus (SLE) and its relation to clinical and 




This study was carried out at the Pediatric Allergy 
and Immunology Clinic at Children’s Hospital of 
Ain Shams University in Cairo. The study was 
approved by the local ethical committee and 
informed consents were taken from the older 
children or the parents before enrollment.  
The study included: 
• Patients with JRA: Twenty-four patients with 
JRA, fulfilling the 1987 American Rheumatism 
Association Revised Criteria for the diagnosis of 
rheumatoid arthritis (11), were included in the 
study. They were 6 males (25%) and 18 females 
(75%) with a mean age of 11.88± 0.0915 years 
(range 4-18 years).  
• Patients with SLE: This group included 17 
patients with SLE fulfilling the 1982 American 
Rheumatism Association Revised Criteria for 
diagnosis of SLE (12). They were 1 male (6%) and 
16 females (94%) with a mean age of 13.47±1.09 
years (range 5-18 years).  
For comparison of our results, two groups were 
included:  
• Patients with rheumatic arthritis: This group 
included 19 patients with rheumatic arthritis (mean 
age 9.74+0.63 years) who were diagnosed 
according to the modified Jones criteria13. 
• Twenty clinically healthy children, whose 
ages and sex were matched with the 
patients, served as a control group.  
Exclusion criteria: 
Patients with renal impairment, congestive heart 
failure, hypertension, diabetes mellitus or acute 
infections were excluded from this study.  
 
The patients were subjected to:  
1. Clinical evaluation:  
A. For patients with JRA (Group I), stress was laid 
on the duration of disease, type of disease onset, 
number of affected joints, activity of arthritis, 
systemic manifestations and medication received. 
Patients were assessed for clinical parameters of 
joint inflammation using the summed joint index 
score14,15. For each of the clinical indices (the joint 
swelling, the pain on motion/joint tenderness and 
limitation of motion), the total articular activity for 
each patient was calculated, considering the 
affected joints only, as follows:  
Activity score = -Sum of the clinical indices for each of 
the affected joints = x  
 joints. affected of Number
 joints. examined all of x of Sum  
B. Patients with SLE (group II): Stress was laid on 
age, sex, signs and symptoms of SLE, duration of 
disease, different system involvement e.g. 
cardiovascular and renal affection and received 
medications received12. Renal involvement: was 
diagnosed by persistent proteinuria of 0.5g/day or 
cellular cast (red blood casts, granular, tubular or 
mixed). Cutaneous vasculitis was diagnosed if any 
of the following skin lesions were present: purpura, 
ulcers, subcutaneous nodules or livedo reticularis. 
Arthitis: was diagnosed if two or more joints 
showed signs of inflammation. Disease activity was 
measured by systemic lupus erythematosus disease 
activity index (SLE-DAI) score3.  




About 5 ml of venous blood were withdrawn from 
each of the control groups and patients and divided 
as follows:  
1. Clotted samples, the obtained serum (by 
centrifugation for 10 min at 1500 rpm) was 
divided into three portions, one for the assay of 
ANA, anti-DNA, C3 and rheumatoid factor, the 
second portion for estimation of kidney function 
test and the third one was stored at -20°C until 
assayed for TNF-α.  
2. A blood sample, on EDTA was taken for ESR 
estimation; another 3ml were also withdrawn 
using chilled syringe and transferred into a 
polypropylene tube containing EDTA (1 mg/ml 
of blood) and aprotinin (500 KIU/ml). 
Centrifugation was done at 1500 rpm for 15 
minutes at 4°C. The obtained plasma was stored 
at -70°C until assay of ADM.  
 
Analytical Methods:  
• Measurement of ESR by Westergren method.  
• Serum creatinine using a modified rate Jaffe 
method on Synchrone CX5 system (Beckman 
Inst., Brea, California, USA).  
• Serum ANA and anti-DNA for SLE patients 
detected by indirect immunofluorescent technique 
(IMMCO diagnosis, NY, USA)  
• Rheumatoid factor by Rose Waaler test.  
• TNF-α: 
Accucyte human TNF-α (CytImmune Science 
Inc., College park, Maryland, USA) is a 
competitive enzyme immunoassay (EIA) which 
measures the natural and recombinant forms of 
the cytokine 16. Goat anti-rabbit antibodies are 
used to capture a specific TNF-α antibody, 
biotinylated TNF-α and sample/standard. The 
biotinylated TNF-α (competitive ligand) and 
samples or standard compete for TNF-α specific 
antibody binding sites. The assay was visualized 
by streptavidin alkaline phosphatase conjugate 
and chromogenic substrate reaction. Results were 
deducted from standard curve plotted on semilog 
paper.  
• Adrenomedullin (ADM):  
Plasma samples were acidified with equal 
volumes of 1% trifuoroacetic acid (TFA), 
followed by centrifugation for 20 minutes at 1500 
rpm at 4°C. At the same time equilibration of the 
C18 column was carried out by washing with 
60% acetonitrite in 1% TFA using 1 ml once 
followed by 1% TFA using 3.0 ml 3 times. 
Plasma solution was then added. After washing 
the column with TFA 1% using 3.0 ml twice, the 
peptide was eluted slowly by the 60% acetonitrite 
in 10% TFA using 3.0 ml once. The eluent was 
collected in polypropylene tubes, then it was 
evaporated to dryness. Prior to assay, the residue 
was dissolved in RIA buffer.  
Adrenomedullin peptide was measured by 
radio- immunoassay technique a kit product of 
Peninsula laboratories (611 Talor wat, Belmont, 
California). The assay was based upon the 
competition of labeled I125 peptide and unlabeled 
peptide (either standard or unknown) binding to a 
limited amount of specific antibodies. As the 
concentration of standard or unknown in the 
reaction increased. The amount of the labeled 
peptide able to bind to the antibody decreased. 
The separation of free and bound antigen was 
achieved via a double antibody precipitation 
followed by decanting. By measuring amount of 
I125 peptide bound as a function of the 
concentration of the unlabeled peptide in standard 
reaction mixtures, it was possible to construct a 
standard curve from which the concentration of 
peptide in unknown sample were determined 17. 
 
Statistical Methods: 
Statistical analysis was done using a software 
package (SPSS) version 9.05. Quantitative variables 
were presented as mean (x) ± standard error of the 
mean (SEM). Comparison between non-parametric 
variables was done using Mann-Whitney U test. 
Correlation of different variables was done using 
Spearman r Correlation test. p values less than 0.05 
were considered significant. To assess the 
diagnostic performance of both the adrenomedullin 
and TNF-α in cases of JRA and pediatric-onset 
SLE, calculation of the diagnostic sensitivity of 
both markers was done at cut-off levels 
corresponding to the 95th percentile of both markers 





The present study included 24 patients with JRA, 15 
(62%) of them had a polyarticular onset, 5 (21%) 
had a pauciarticular onset and 4 (17%) had a 
systemic onset- type of JRA. The duration of the 
disease ranged from 1-13 years (mean 4.61±4.7 
years). According to the summed joint index score, 
the disease activity score in our patients ranged from 
0-6.25. The ESR in the studied JRA patients ranged 
between 5 and 100 mm/hr (mean 37.92±5.8 mm/hr). 
The mean value of TNF-α in the sera of JRA 
patients (73.88±11.60 pg/ml) was significantly 
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increased compared to rheumatic arthritis patients 
(13.42±1.8 pg/ml) and healthy controls (4.35± 0.30 
pg/ml), but  was not significantly different from that 
of SLE patients (48.82±7.5 pg/ml) (Table 1). On the 
other hand, the mean value of ADM in the plasma of 
JRA patients (mean 156.50±22.4 pg/ml) was 
significantly increased compared to SLE (95.12± 
15.7 pg/ml), rheumatic arthritis patients (45.21± 
5.98 pg/ml) and controls (17.11± 3.28pg/ml)  (Table 
2, Fig1).  
Both serum TNF-α and plasma ADM levels were 
significantly higher in systemic onset-JRA 
(139.75+18.5 and 260.25+28.6 pg/ml, respectively) 
compared to the pauciarticular-onset type 
(33.8+3.04 and 93.4+9.35 pg/ml, respectively), but 
not significantly different from the polyarticular 
onset cases (69.97+8.45 and 149.87+21.15 pg/ml, 
respectively). Similar to TNF-α, the mean ADM 
level was not significantly different in pauciarticular 
onset as compared to polyarticular onset cases 
(Tables 3 and 4). 
Plasma ADM could be positively correlated to the 
activity score index, and ESR in JRA patients was 
found. Furthermore, our study demonstrated a 
highly significant positive correlation between 
plasma ADM and serum TNF-α  (Fig 2 and 3). 
 
Pediatric-onset SLE patients: 
Seventeen patients with pediatric-onset SLE were 
included in the present study;  the duration of the 
disease ranged from 2-9 years (mean 4.94±5.1 
years). Six of our patients were diagnosed as having 
lupus nephritis. Eight patients had cardiovascular 
disorders; four had pericardial affection, one had 
wall motion abnormality and 2 patients showed 
endocardial lesions, all of which were detected by 
echocardiogram, also one patient had ectasia of the 
left coronary system detected by coronary 
angiography. Six patients had cutaneous vasculitis in 
the form of purpura, ulcers and livedo reticularis 
According to the SLE-DAI, the indices of our 
patients ranged from 2 to 16. Their ESR values 
ranged between 5 and 100 mm/hr (mean 38.82±7.54 
mm/hr), their TNF-α between 8 and 124 pg/ml 
(mean 48.82±7.43 pg/ml) and their ADM ranged 
between 13 and 250 pg/ml (mean 95.12±15.76 
pg/ml).  
The mean values of serum TNF-α did not vary 
significantly in SLE with arthritis, CVS disorders or 
lupus nephritis (mean= 57.5±9.2, 54.0±8.6, and 
63.0±7.5 pg/ml, respectively) in comparison to cases 
not suffering from these disorders (mean of 
44.09±6.4, 44.22±6.4, and 39.0±6.9 pg/ml, 
respectively). On the other hand, the mean values of 
plasma ADM were significantly higher in SLE 
patients with arthritis and CVS disorders (mean= 
149.5±15.8 and 128.63±16 pg/ml, respectively) 
compared to SLE patients without such involvement 
(mean= 65.45±10.5 and 65.33±12.08 pg/ml, 
respectively) (Figure 4). Though serum TNF-α and 
ADM levels were found to correlate positively to 
ESR in SLE patients (r=0.52 and 0.62, respectively), 
and to one another (r=0.74), no such correlation 
could link it to the  SLE-DAI.  
Based on results of the rheumatic patients, cut-off 
values of 31 pg/ml for TNF-α and 80 pg/ml for 
ADM were chosen corresponding to 95th percentile. 
The calculated diagnostic sensitivity was 62.5% for 
TNF-α compared to 75% for ADM in JRA. While 
the diagnostic sensitivity was 100% in systemic-
onset JRA and 73.3% in polyarticular-onset for 
ADM, it was 75% and 66.6%, respectively for  
TNF-α. In SLE patients, the diagnostic sensitivity 
was 52.9% for TNF-α, and 70.6% for ADM. 
Furthermore, the diagnostic sensitivity of ADM was 
more than 80% in SLE patients who had nephritis, 




ADM: adrenomedullin; JRA: juvenile rheumatoid arthritis; 
SLE : systemic lupus erythematosus. 
@ p< 0.05 in comparison to the mean value of JRA patients 
β  p< 0.01 in comparison to the mean value of JRA patients 
§   p< 0.05 in comparison to the mean value of SLE patients 
*  p< 0.001 in comparison to the mean value of SLE patients. 
 
Fig. (1): Comparison of mean values of plasma 
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Fig. (2): Positive correlation between plasma 
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Fig. (3): Positive correlation between serum 





Fig. (4): Variation of mean values of plasma ADM in SLE 
patients according to systemic involvement 
 
 
Table (1) : Comparison of mean values of serum TNF-α in the patients and controls.  
0BTNF-α (pg/ml) Mean±SEM Z* P* Z** P** 
  JRA 
  SLE 
  Rheumatic arthritis 





















JRA: juvenile rheumatoid arthritis; SLE : systemic lupus erythematosus;  TNF-α: tumor necrosis factor-α. * In comparison 
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Table (2): Comparison of mean values of plasma ADM in the patients and controls.  
1BADM (pg/ml) Mean±SEM Z* P* Z** P** 
  JRA 
  SLE 
  Rheumatic arthritis  




















  <0.001 
ADM: adrenomedullin; JRA: juvenile rheumatoid arthritis; SLE : systemic lupus 
erythematosus. * In comparison to JRA patients. ** In comparison to SLE patients.  
 
 Table (3): Comparison of mean values of serum TNF-α in patients with different JRA subtypes. 



















JRA: juvenile rheumatoid arthritis;  TNF-α: tumor necrosis factor-α. * in comparison to systemic-onset 
JRA. ** in comparison to polyarticular- onset JRA. 
 
Table (4): Comparison of mean values of plasma ADM in patients with different JRA subtypes. 



















ADM: adrenomedullin; JRA: juvenile rheumatoid arthritis.* in comparison to systemic-onset JRA.  
** in comparison to polyarticular- onset JRA. 
 
Table (5): The diagnostic sensitivity of TNF-α and ADM in  JRA and SLE patients at the 
chosen cut off values (95% specificity).  
Cut-off value :  TNF-α = 31 pg/ml ADM = 80 pg/ml 
JRA = 62.5% (15/24) JRA : 75% (18/24) 
Systemic – onset JRA  
Polyarticular–onset JRA  




Systemic– onset JRA  
Polyarticular–onset JRA  



















TNF-α serum levels in JRA patients were 
significantly increased compared to those in 
rheumatic patients and normal healthy controls. Our 
results support the previously reported role of TNF-
α as an important mediator of immunity and 
inflammation. Because of its biological activities 
(activation of neutrophils, release of arachidonic 
acid metabolites from synovial cells, induction of 
cartilage resorption and inhibition of proteoglycan 
release in cartilage), it is considered one of the 
potential mediators of chronic inflammation in 
rheumatoid arthritis 18. Borzi et al. 18, evaluated the 
serum levels of TNF-α in patients with RA, SLE 
and progressive systemic sclerosis (PSS) and 
reported much higher TNF-α serum levels in 
patients with RA when compared to normal 
controls and to other connective tissue disease 
patients. They stated that TNF-α is one of the 
potential mediators of chronic inflammation in RA 
patients, and suggested that TNF-α played a central 
role in the pathogenesis of RA. Similarly, a study 
done by Altomonte and his coworkers19 revealed 
high levels of serum TNF-α in RA patients 
compared to matched healthy controls.  
Although the mean TNF-α level seemed higher 
in our JRA patients compared to SLE patients, the 
difference did not reach statistical significance. In 
agreement with our results, Maury and Teppo20, in 
their study, reported that serum TNF-α levels in 
SLE patients were lower than in RA patients, but 
the difference was not statistically significant. On 
comparing the TNF-α expression in different JRA 
subtypes, the highest levels of serum TNF-α were 
observed in systemic onset-JRA followed by the 
polyarticular- onset and pauciarticular onset-types 
Tomoum et al. 
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with significantly higher levels in systemic- onset 
compared to pauciarticular onset-JRA. Our findings 
are in agreement with the results of Mangge et al.,21 
who studied IL-1 beta, IL-2 and soluble IL-2 
receptors and reported that systemic JRA showed 
the most significant elevations of plasma cytokines, 
followed by the polyarticular and pauciarticular 
varieties. Similar results were reported by 
Altomonte et al.19, who stated that serum IL-1 beta 
and TNF-α appear to correlate with systemic 
inflammation, and systemic features of RA may 
result from dissemination of cytokines produced in 
the synovium 
These findings were explained by Moore 22 who 
evaluated the interrelation of Th1/Th2 immune 
response in the immunopathogenesis of JRA and 
their effect on cytokine release. They indicated a 
proinflammatory response in systemic onset-JRA 
manifested by increased secretion of IL-6, while an 
anti-inflammatory response has been noted in the 
pauciarticular-onset type evident by the increase of 
IL-4 mRNA and IL-10 mRNA.  
In the current study, the ADM plasma levels 
were highest in patients with JRA followed by SLE, 
rheumatic arthritis and healthy controls. Yudoh et 
al.10, demonstrated that plasma ADM expression 
was significantly higher in patients with RA than 
SLE, polymyositis/dermatomyositis, mixed 
connective tissue disease, osteoarthritis and normal 
controls. A recent study by Matsushita et al.23, 
reported the presence of ADM mRNA in synovial 
cells from rheumatoid patients.  Similar to our 
findings in TNF-α, the highest mean value of 
plasma ADM was seen in systemic onset-JRA 
followed by polyarticular onset-JRA with a 
statistically significant difference between systemic 
onset and pauciarticular onset-types. Our data come 
in accordance to the conclusions of  Sugo et al.24 , 
and Dilorio et al.25, who noted that ADM 
production in vascular smooth muscle cells is 
highly augmented by TNF-α, IL-1 and 
lipopolysaccharide.  
Plasma ADM was found to correlate with 
clinical (summed activity score index) and 
biochemical (ESR, TNF-α) markers of activity in 
our JRA patients, which suggests that it can be an 
important indicator of disease activity. Similarly, 
Yudoh et al.10 reported a positive significant 
correlation between plasma ADM level and joint 
activity score, serum TNF-α and other laboratory 
measures of inflammation (fibrinogen, haptoglobin, 
C-reactive protein, α-1-antitrypsin) in JRA patients. 
Hence, it may be concluded that serum ADM level 
can be used as a marker of disease activity in RA 
patients. 
Serum TNF-α in our SLE patients showed no 
significant difference in subjects with or those 
without arthritis, CVS disorders or lupus nephritis. 
Similarly, Al-Jandi et al.26, studied TNF-α levels in 
SLE patients with nephritic involvement and found 
no significant difference compared to the rest of 
patients. Concerning the plasma ADM levels in our 
series, the highest mean plasma level of ADM was 
observed in SLE patients with arthritis followed by 
SLE with cardiovascular disorders then SLE with 
lupus nephritis. Also, SLE patients with CVS and 
arthritis were found to have significantly higher 
ADM levels as compared to SLE patients without 
these disorders. This may be explained by the fact 
that ADM is directly involved in the pathogenesis 
of these two conditions. ADM secretion, especially 
in cardiovascular tissues, is regulated by 
mechanical stressors such as shear stress, and 
lipopolysaccharide, hormones as angiotensin II and 
metabolic factors as hypoxia or ischemia. Elevation 
of ADM due to overproduction in response to any 
of these stimuli in pathological conditions may 
explain the rise in their levels in cardiovascular 
diseases27,28. ADM was not significantly different in 
SLE patients with lupus nephritis compared to those 
without. However, in 1998, Kubo and colleagues 
demonstrated that chronic glomerulonephritis was 
associated with high levels of ADM8. Cheung et 
al.29, noted that ADM, lowers systemic vascular 
resistance and acts as a natriuretic and diuretic 
peptide. These properties resemble those of atrial 
natriuretic peptide which has an important role in 
the progression of renal disease. Larger scale 
studies are needed to verify the findings. 
The plasma ADM levels were found to 
correlate significantly with ESR and TNF-α levels, 
but not with SLE-DAI. In accordance to our results, 
Yudoh and his colleagues10 and Cheung et al.29, 
revealed a significant correlation between ADM 
and TNF-α levels in SLE patients and a poor 
correlation between ADM and SLE-DAI and 
biochemical markers (fibrinogen, IL-6, C-reactive 
protein, α-1-antitrypsin). While the rise of ADM 
could be secondary to the rise in inflammatory 
cytokines as TNF-α29, it is unclear why ADM 
levels correlated with disease activity only in JRA.    
TNF-α is a well established marker for disease 
activity in RA as suggested previously by many 
researchers 22, 30, so trying to evaluate the usefulness 
of ADM in comparison to TNF-α, we chose a cut-
off value depending on the values of the rheumatic 
arthritis patients involved, and compared the 
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diagnostic sensitivity for both.  With the cut off 
values of 31 pg/ml for TNF-α and 80 pg/ml for 
ADM, the diagnostic sensitivity in JRA was 62.5% 
for the former compared to 75% for the latter. 
While the diagnostic sensitivity of ADM was 100% 
in systemic-onset JRA and 73.3% in polyarticular-
onset, it was 75% and 66.6%, respectively for TNF-
α. In SLE patients, the diagnostic sensitivity was 
52.9% for TNF-α and 70.6% for ADM. 
Furthermore, the diagnostic sensitivity of ADM was 
more than 80% in SLE patients with nephritis, 
arthritis or cardiovascular system involvement.  No 
similar data could be traced in the literature for 
comparison . 
In conclusion, plasma ADM levels were 
significantly higher in patients  with JRA and SLE 
compared to rheumatic patients and  healthy 
controls. It is suggested that ADM may be directly 
involved in arthritic changes among those patients. 
Plasma ADM levels correlated with the summed 
clinical activity score index and biochemical 
activity markers in JRA suggesting that it can be 
used as an indicator of disease activity in JRA. In 
SLE, ADM expression correlated with ESR and 
TNF- α  and it might be useful in the evaluation of 
patients with systemic involvement such as those 
with arthritis and cardiac disorders. The prognostic 
value of ADM levels in rheumatologic diseases 
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